JP2008545772A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008545772A5 JP2008545772A5 JP2008515197A JP2008515197A JP2008545772A5 JP 2008545772 A5 JP2008545772 A5 JP 2008545772A5 JP 2008515197 A JP2008515197 A JP 2008515197A JP 2008515197 A JP2008515197 A JP 2008515197A JP 2008545772 A5 JP2008545772 A5 JP 2008545772A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- group
- phenyl
- methyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000004419 alkynylene group Chemical group 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 229930002330 retinoic acid Natural products 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical group C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 1
- GYYUWFNCIFKBEJ-HFWQAORDSA-N (E)-N-(2-aminophenyl)-3-[4-(2-morpholin-4-ylethoxyiminomethyl)phenyl]prop-2-enamide hydrochloride Chemical compound Cl.NC1=CC=CC=C1NC(=O)\C=C\C(C=C1)=CC=C1C=NOCCN1CCOCC1 GYYUWFNCIFKBEJ-HFWQAORDSA-N 0.000 claims 1
- VRNRFXXEURJIAZ-SWYYNQHESA-N (E)-N-(2-aminophenyl)-3-[4-[(4-nitrophenyl)methoxyiminomethyl]phenyl]prop-2-enamide Chemical compound NC1=CC=CC=C1NC(=O)\C=C\C(C=C1)=CC=C1C=NOCC1=CC=C([N+]([O-])=O)C=C1 VRNRFXXEURJIAZ-SWYYNQHESA-N 0.000 claims 1
- ATRIOAVZXXVRHX-FRFBVDEYSA-N (E)-N-hydroxy-3-[4-[(2,3,4,5,6-pentafluorophenyl)methoxyiminomethyl]phenyl]prop-2-enamide Chemical compound ONC(\C=C\C1=CC=C(C=C1)C=NOCC1=C(C(=C(C(=C1F)F)F)F)F)=O ATRIOAVZXXVRHX-FRFBVDEYSA-N 0.000 claims 1
- LBOUHDMYVURTMA-AATRIKPKSA-N (e)-3-(4-formylphenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(C=O)C=C1 LBOUHDMYVURTMA-AATRIKPKSA-N 0.000 claims 1
- UQKGJRYLFMUHGZ-RVOOOTTKSA-N (e)-3-[4-(phenylmethoxyiminomethyl)phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1C=NOCC1=CC=CC=C1 UQKGJRYLFMUHGZ-RVOOOTTKSA-N 0.000 claims 1
- LJTDURKDHMOLIM-OPUQBVRYSA-N (e)-3-[4-[(4-nitrophenyl)methoxyiminomethyl]phenyl]-n-sulfanylprop-2-enamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1CON=CC1=CC=C(\C=C\C(=O)NS)C=C1 LJTDURKDHMOLIM-OPUQBVRYSA-N 0.000 claims 1
- YNBOWUIQBRECPS-PFMZDYLOSA-N (e)-3-[4-[(e)-(4-nitrophenyl)methoxyiminomethyl]phenyl]prop-2-enoic acid Chemical compound C1=CC(/C=C/C(=O)O)=CC=C1\C=N\OCC1=CC=C([N+]([O-])=O)C=C1 YNBOWUIQBRECPS-PFMZDYLOSA-N 0.000 claims 1
- WNSMZNNXMAXKHW-CUFFHGBCSA-N (e)-n-hydroxy-3-[3-(2-morpholin-4-ylethoxyiminomethyl)phenyl]prop-2-enamide;hydrochloride Chemical compound Cl.ONC(=O)\C=C\C1=CC=CC(C=NOCCN2CCOCC2)=C1 WNSMZNNXMAXKHW-CUFFHGBCSA-N 0.000 claims 1
- KKMCPDKFGBXVNL-VALNIMGKSA-N (e)-n-hydroxy-3-[4-(2-morpholin-4-ylethoxyiminomethyl)phenyl]prop-2-enamide Chemical compound C1=CC(/C=C/C(=O)NO)=CC=C1C=NOCCN1CCOCC1 KKMCPDKFGBXVNL-VALNIMGKSA-N 0.000 claims 1
- DHSYUAULSBHRPH-RVOOOTTKSA-N (e)-n-hydroxy-3-[4-(phenylmethoxyiminomethyl)phenyl]prop-2-enamide Chemical compound C1=CC(/C=C/C(=O)NO)=CC=C1C=NOCC1=CC=CC=C1 DHSYUAULSBHRPH-RVOOOTTKSA-N 0.000 claims 1
- NRCCSDVEUWXOMG-UHFFFAOYSA-N 3-(4-formylphenyl)propanoic acid Chemical class OC(=O)CCC1=CC=C(C=O)C=C1 NRCCSDVEUWXOMG-UHFFFAOYSA-N 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010059866 Drug resistance Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 125000005336 allyloxy group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 125000003147 glycosyl group Chemical group 0.000 claims 1
- 150000002443 hydroxylamines Chemical class 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- 238000009830 intercalation Methods 0.000 claims 1
- IHHUORPGTIDVFD-VRDSVTSBSA-N methyl 4-[[[4-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methylideneamino]oxymethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CON=CC1=CC=C(\C=C\C(=O)NO)C=C1 IHHUORPGTIDVFD-VRDSVTSBSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- -1 nitro halogen Chemical class 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05012561 | 2005-06-10 | ||
| PCT/EP2006/062790 WO2006131482A1 (en) | 2005-06-10 | 2006-05-31 | Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumour agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008545772A JP2008545772A (ja) | 2008-12-18 |
| JP2008545772A5 true JP2008545772A5 (enExample) | 2009-07-16 |
Family
ID=35004351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008515197A Withdrawn JP2008545772A (ja) | 2005-06-10 | 2006-05-31 | 抗腫瘍薬として有用なケイ皮酸、フェニルプロピオル酸およびフェニルプロピオン酸誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7816386B2 (enExample) |
| EP (1) | EP1893561A1 (enExample) |
| JP (1) | JP2008545772A (enExample) |
| KR (1) | KR20080040665A (enExample) |
| CN (1) | CN101193854A (enExample) |
| AR (1) | AR053894A1 (enExample) |
| AU (1) | AU2006256769A1 (enExample) |
| BR (1) | BRPI0611730A2 (enExample) |
| CA (1) | CA2607184A1 (enExample) |
| EA (1) | EA013845B1 (enExample) |
| MX (1) | MX2007015293A (enExample) |
| TW (1) | TW200718691A (enExample) |
| WO (1) | WO2006131482A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI429628B (zh) | 2010-03-29 | 2014-03-11 | Univ Taipei Medical | 吲哚基或吲哚啉基羥肟酸化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3763213A (en) * | 1971-11-10 | 1973-10-02 | R Heck | Introduction of organic groups into ethylenically unsaturated carboxylic nitriles using a group viii metal salt |
| US6248752B1 (en) * | 1998-02-27 | 2001-06-19 | Charles Duane Smith | Azabicyclooctane compositions and methods for enhancing chemotherapy |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| US6800618B2 (en) | 2001-05-07 | 2004-10-05 | The United States Of America As Represented By The Secretary Of The Army | Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof |
| DE10225635C1 (de) * | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
-
2006
- 2006-05-24 TW TW095118491A patent/TW200718691A/zh unknown
- 2006-05-31 EA EA200702668A patent/EA013845B1/ru not_active IP Right Cessation
- 2006-05-31 KR KR1020087000035A patent/KR20080040665A/ko not_active Ceased
- 2006-05-31 US US11/917,039 patent/US7816386B2/en not_active Expired - Fee Related
- 2006-05-31 WO PCT/EP2006/062790 patent/WO2006131482A1/en not_active Ceased
- 2006-05-31 EP EP06777257A patent/EP1893561A1/en not_active Withdrawn
- 2006-05-31 BR BRPI0611730-9A patent/BRPI0611730A2/pt not_active IP Right Cessation
- 2006-05-31 MX MX2007015293A patent/MX2007015293A/es active IP Right Grant
- 2006-05-31 CA CA002607184A patent/CA2607184A1/en not_active Abandoned
- 2006-05-31 JP JP2008515197A patent/JP2008545772A/ja not_active Withdrawn
- 2006-05-31 CN CNA2006800205630A patent/CN101193854A/zh active Pending
- 2006-05-31 AU AU2006256769A patent/AU2006256769A1/en not_active Abandoned
- 2006-06-09 AR ARP060102416A patent/AR053894A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514316A5 (enExample) | ||
| JP2011057693A5 (enExample) | ||
| JP2010532768A5 (enExample) | ||
| JP2004518723A5 (enExample) | ||
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| HUP0301169A2 (hu) | 9-Helyzetben helyettesített minociklinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| JP5149177B2 (ja) | 増殖性疾患の治療のための、チューブリンポリマー化の１，２，３−トリアゾール系抑制剤 | |
| JP2011504903A5 (enExample) | ||
| US11312737B2 (en) | Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof | |
| JP2007509928A5 (enExample) | ||
| US10464896B2 (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| JP2017512777A (ja) | 抗真菌化合物の調製方法 | |
| JP2011517697A5 (enExample) | ||
| RU2008136762A (ru) | Циклические сульфоны как ингибиторы васе | |
| EP3022176B1 (en) | Azacyclic constrained analogs of fty720 | |
| JP2012519703A5 (enExample) | ||
| JP2008500378A5 (enExample) | ||
| JP2005527575A5 (enExample) | ||
| RU2313524C2 (ru) | МИТИЛИНДОЛЫ И МЕТИЛПИРРОЛОПИРИДИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ α-1-АДРЕНЕРГИЧЕСКИХ АГОНИСТОВ | |
| RU2006138035A (ru) | Применение производного фенотиазина для профилактики и/или лечения потери слуха | |
| JP2008542428A5 (enExample) | ||
| US20220242893A1 (en) | Amide-linked conjugate compounds and uses thereof | |
| CN1337881A (zh) | 有机磷化合物预防或治疗感染的应用 | |
| JP2008524165A5 (enExample) | ||
| JP2008518024A5 (enExample) |